Kaleido

Verwendung der Mittel

Scale manufacturing capacity; accelerate commercialization and launch of Kaleido 2 in Europe; support regulatory activities and FDA preparations for U.S. market entry.

Lead Investor

Alle Investoren (6)

• Innovation IndustriesLead
• EQT Life Sciences
• Partners in Equity (Partners in Equity B.V.)
• Invest‑NL
• Health Innovations (Health Innovations B.V.)
• INKEF Capital

Analyse-Artikel

ViCentra schließt Series‑D über 85 Mio. $ zur Skalierung des Kaleido‑Insulin‑Patch‑Pumps

Artikel lesen